pancrelipase lipase, pancrelipase amylase, and pancrelipase protease
PANCREAZE (pancrelipase lipase, pancrelipase amylase, and pancrelipase protease) is lipases, proteases, and amylases that catalyze the hydrolysis of fats to monoglyceride, glycerol and free fatty acids, proteins into peptides and amino acids, and starches into dextrins and short chain sugars such as maltose and maltriose in the duodenum and proximal small intestine, thereby acting like digestive enzymes physiologically secreted by the pancreas. Approved for exocrine pancreatic insufficiency in adult. First approved in 2010.
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
PANCREAZE is an oral, delayed-release capsule containing a combination of pancrelipase enzymes (lipase, amylase, and protease) approved in 2010 for treating exocrine pancreatic insufficiency in adults. The product works by replacing missing pancreatic digestive enzymes, catalyzing the breakdown of fats into monoglycerides and fatty acids, proteins into peptides and amino acids, and starches into simple sugars in the small intestine. It functions as a physiologic replacement therapy, mimicking the digestive function of a healthy pancreas.
lipases, proteases, and amylases that catalyze the hydrolysis of fats to monoglyceride, glycerol and free fatty acids, proteins into peptides and amino acids, and starches into dextrins and short chain sugars such as maltose and maltriose in the duodenum and proximal small intestine, thereby acting…
Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
PANCREAZE supports roles including brand managers, medical science liaisons (MSLs), and field sales representatives focused on gastroenterology and hepatology specialties, though limited market share suggests smaller team sizes compared to CREON. Success in this role requires deep knowledge of pancreatic disease management, gastroenterologist relationships, and hospital formulary navigation. Currently, 6 open positions are linked to this product, indicating modest but active talent recruitment for the brand.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo